Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L)

BACKGROUND: Synchronous oligometastatic non-small cell lung cancer (NSCLC) is generally characterised by the limited number of metastases at the time of diagnosis. Several clinical trials have shown that local ablative therapy (LAT) at all sites of the disease might be beneficial for patients with o...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyawaki, Taichi, Kenmotsu, Hirotsugu, Harada, Hideyuki, Ohde, Yasuhisa, Chiba, Yasutaka, Haratani, Koji, Okimoto, Tamio, Sakamoto, Tomohiro, Wakuda, Kazushige, Ito, Kentaro, Uemura, Takehiro, Sakata, Shinya, Kogure, Yoshihito, Nishimura, Yasumasa, Nakagawa, Kazuhiko, Yamamoto, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524804/
https://www.ncbi.nlm.nih.gov/pubmed/34663250
http://dx.doi.org/10.1186/s12885-021-08851-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524804/
https://www.ncbi.nlm.nih.gov/pubmed/34663250
http://dx.doi.org/10.1186/s12885-021-08851-z

Ejemplares similares